WED Foundation and XenoPort, Inc. (XNPT) Announce Launch of New “Patient Odyssey” Survey Assessing Day-to-Day Impact of RLS/WED on Both Patients and Loved Ones  
9/26/2013 9:52:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCHESTER, Minn. & SANTA CLARA, Calif.--(BUSINESS WIRE)--The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq: XNPT) announced today that they have launched a new “Patient Odyssey” survey, aimed at measuring the challenges of long-term disease management, quality of life (QoL) impact and emotional burden associated with restless legs syndrome/Willis-Ekbom Disease (RLS/WED) among patients, as well as the impact of the disease on relationships with spouses or partners. The survey kicks off during this year’s National RLS/WED Awareness Week, dedicated to the continuation of education that improves diagnosis and treatment of the disease.

Help employers find you! Check out all the jobs and post your resume.